|
|
Blood, 1 August 2004, Vol. 104, No. 3, pp. 788-794.
Prepublished online as a Blood First Edition Paper on March 2, 2004; DOI 10.1182/blood-2003-08-2763.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
Yean K. Lee,
Nancy D. Bone,
Ann K. Strege,
Tait D. Shanafelt,
Diane F. Jelinek, and
Neil E. Kay
From the Division of Hematology, Department of Medicine, Mayo Clinic; and Department of Immunology, Mayo Clinic, Rochester, MN.
We recently reported that chronic lymphocytic leukemia (CLL) cells synthesize and release vascular endothelial growth factor (VEGF) under normoxic and hypoxic conditions. CLL B cells also express VEGF membrane receptors (VEGF-R1 and VEGF-R2), suggesting that they use VEGF as a survival factor. To assess the mechanism of apoptosis resistance related to VEGF, we determined the impact of VEGF on CLL B cells, and we studied the impact of epigallocatechin-3-gallate (EGCG), a known receptor tyrosine kinase (RTK) inhibitor, on VEGF receptor status and viability of CLL B cells. VEGF165 significantly increased apoptotic resistance of CLL B cells, and immunoblotting revealed that VEGF-R1 and VEGF-R2 are spontaneously phosphorylated on CLL B cells. EGCG significantly increased apoptosis/cell death in 8 of 10 CLL samples measured by annexin V/propidium iodide (PI) staining. The increase in annexin V/PI staining was accompanied by caspase-3 activation and poly–adenosine diphosphate ribose polymerase (PARP) cleavage at low concentrations of EGCG (3 µg/mL). Moreover, EGCG suppressed the proteins B-cell leukemia/lymphoma-2 protein (Bcl-2), X-linked inhibitor of apoptosis protein (XIAP), and myeloid cell leukemia-1 (Mcl-1) in CLL B cells. Finally, EGCG (3-25 µg/mL) suppressed VEGF-R1 and VEGF-R2 phosphorylation, albeit incompletely. Thus, these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. G. Longo, L. Laurenti, S. Gobessi, S. Sica, G. Leone, and D. G. Efremov
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Blood,
January 15, 2008;
111(2):
846 - 855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, and E. Morra
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia
Haematologica,
October 1, 2007;
92(10):
1367 - 1374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pillozzi, M. F. Brizzi, P. A. Bernabei, B. Bartolozzi, R. Caporale, V. Basile, V. Boddi, L. Pegoraro, A. Becchetti, and A. Arcangeli
VEGFR-1 (FLT-1), {beta}1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome
Blood,
August 15, 2007;
110(4):
1238 - 1250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Carew, S. T. Nawrocki, Y. V. Krupnik, K. Dunner Jr, D. J. McConkey, M. J. Keating, and P. Huang
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL
Blood,
January 1, 2006;
107(1):
222 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. McCarty and K. I. Block
Multifocal Angiostatic Therapy: An Update
Integr Cancer Ther,
December 1, 2005;
4(4):
301 - 314.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Das, H. Yeger, R. Tsuchida, R. Torkin, M. F.W. Gee, P. S. Thorner, M. Shibuya, D. Malkin, and S. Baruchel
A Hypoxia-Driven Vascular Endothelial Growth Factor/Flt1 Autocrine Loop Interacts with Hypoxia-Inducible Factor-1{alpha} through Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathway in Neuroblastoma
Cancer Res.,
August 15, 2005;
65(16):
7267 - 7275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Battle, J. Arbiser, and D. A. Frank
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
Blood,
July 15, 2005;
106(2):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Till, D. G. Spiller, R. J. Harris, H. Chen, M. Zuzel, and J. C. Cawley
CLL, but not normal, B cells are dependent on autocrine VEGF and {alpha}4{beta}1 integrin for chemokine-induced motility on and through endothelium
Blood,
June 15, 2005;
105(12):
4813 - 4819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Hu, N. Haney, D. Kropp, A. F. Kabore, J. B. Johnston, and S. B. Gibson
Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia Cells from Apoptosis through LPA Receptor Activation of the Anti-apoptotic Protein AKT/PKB
J. Biol. Chem.,
March 11, 2005;
280(10):
9498 - 9508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Chiorazzi, K. R. Rai, and M. Ferrarini
Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
February 24, 2005;
352(8):
804 - 815.
[Full Text]
[PDF]
|
|
|
| |
